Healthcare Author: Contributor, Yidu Tech Dec 16, 2021 02:04 PM (GMT+8)

On 16 December, Zhaoke Ophthalmology (SEHK: 6622) and HappyLife Technology ("HLT"), an affiliate of Yidu Tech Inc. ("Yidu Tech", SEHK: 2158), announced to have signed a Letter of Intent with an objective to accelerate the development of innovative clinical research programs for the Chinese ophthalmic market.

handshake

[HONG KONG, 16 December 2021, Yidu Tech] – On 16 December, Zhaoke Ophthalmology (SEHK: 6622) and HappyLife Technology ("HLT"), an affiliate of Yidu Tech Inc. ("Yidu Tech", SEHK: 2158), announced to have signed a Letter of Intent with an objective to accelerate the development of innovative clinical research programs for the Chinese ophthalmic market. 

Zhaoke Ophthalmology is a leading ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs. Yidu Tech is a healthcare big data and artificial intelligence solutions provider, and HLT is an affiliate of Yidu Tech which focuses on life sciences solutions. This newly established partnership aims to jointly deliver better medical care and support to eye disease patients in China.

According to the LOI, the partnership between Zhaoke Ophthalmology and HLT will initially focus on the following three areas:

• Nurturing talent for clinical research

The two parties will provide clinical research education programs to healthcare professionals at the clinical trial centers, with an aim to further good clinical trial practices and understanding.

• Building a clinical research network

The two parties will leverage their resources and build a joint clinical research network, with the aim to improve product development efficiency and lifecycle maintenance optimization.

• Developing a digitalized clinical research model

With the help of Zhaoke Ophthalmology's strong research and development capability in ophthalmic drugs and HLT's technological expertise, the two parties will work together to help transform the clinical research model into a more digital one. This will lead to initiatives such as introducing virtual clinical trials, with the aim to improve clinical trial performance.

Dr. Li Xiaoyi (Benjamin), Chairman and CEO of Zhaoke Ophthalmology, said, "Favourable policies have been encouraging and supporting the innovative development of the pharmaceutical industry, especially the ophthalmic market, as part of China's digital economy. As one of the leading ophthalmic pharmaceutical companies in China, we are very honored to partner with Yidu Tech and its life science solution unit HappyLife Tech, to further enhance and optimize the clinical research environment of the industry. We strongly believe that by leveraging Zhaoke Ophthalmology and HappyLife Tech's strong R&D capabilities and vast resources in the ecosystem, we will be able to facilitate the digital development and construction of ophthalmology clinical research in China, thus providing better medical solutions for patients."

Ms. Gong Yingying (Rujing), Chairlady, CEO and Founder of Yidu Tech said, "The strategic partnership with Zhaoke Ophthalmology is another important milestone for Yidu Tech in life sciences innovation and applications. 'Value-based precision healthcare accessible to everyone' is the mission of Yidu Tech. We are a strong believer in the value of AI technology to enhance the medical industry and we will continue to invest in it, to support the improvement of people's health and wellbeing in China."

Mr. Xu Jiming, Co-founder and Senior Vice President of Yidu Tech, and CEO of HappyLife Tech, said, "HappyLife Tech is committed to providing patients with truly personalized healthcare, working with partners to create an integrated ecosystem that provides full support in the patient's journey from diagnosis to treatment. The cooperation between HappyLife Tech and Zhaoke Ophthalmology is an important step to implement this strategy. I believe that this partnership will enable both parties to build and share values in the field of clinical research, and to benefit more patients by continuously driving the development of the healthcare industry."